SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

NJTC INVESTMENT FUND, LP

(Last)

(First)

(Middle)

1001 BRIGGS ROAD

SUITE 280

(Street)

MOUNT LAUREL

08054

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/25/2008

3. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B 10% Convertible Preferred Stock⁽¹⁾	⁽²⁾	⁽²⁾	Common Stock	2,209,945⁽²⁾⁽³⁾	⁽²⁾	D
Warrants (right to buy)	06/26/2008	10/22/2009	Series B 10% Convertible Preferred Stock	300	$2,500	D

Explanation of Responses:

1. The transactions reported herein by the Reporting Person were previously filed on the appropriate beneficial ownership forms under the name of James T. Gunton, a General Partner of the Reporting Person.

2. Each share of Series B 10% Cumulative Convertible Preferred Stock (the "Series B Stock") had a stated value of $100.00 (the "Series B Stated Value"), and was convertible into that number of shares of the Company's common stock, $0.001 par value per share (the "Common Stock") equal to the Series B Stated Value at a conversion price of $0.90, and had no expiration date.

3. The holdings reported in this Form 3, including the footnotes herein, reflect the twenty-five-for-one reverse stock split of CytoSorbents Corporation Common Stock, which was effected pursuant to approval of a majority of its stockholders on December 3, 2014.

	NJTC Investment Fund, LP, By: /s/ James T. Gunton, General Partner	01/13/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.